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those 45–64s, and 30% of those 65. The mean annual
cost was $2,200; with 0 comorbidities: $1,200; with 1:
$2,000; with 1: $5,200. The R2 for the regression with-
out complications 0.0085 (0.85% of log charges ex-
plained by age and gender). The R2 with complications
was 0.1121 (11% explained by age, gender and compli-
cations). This increase was highly significant (P  0.001).
CONCLUSIONS: Costs increased 13 times more due to
complications than age on a log scale. Substantial savings
may be realized by MCOs who manage their member’s
diabetes well.
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Complications of Type 2 diabetes mellitus (DM) increase
costs to the healthcare provider. Age is correlated with
complications as well as costs. OBJECTIVE: To estimate
diabetes-related costs due to complications separately
from age. METHODS: Members with Type 2 DM were
selected by ETG group from PharMetric’s Integrated
Outcomes database during 1997. Charges to the mem-
ber’s MCO for ED, pharmacy, in- and out-patient ser-
vices were tallied over CY 1997. Members were classi-
fied: (1) as having 0,1, or 1 complications (nephropathy,
retinopathy, neuropathy, or CAD), and (2) by age: 18,
18–44, 45–64, or 65. A regression of age and gender
on ln(charges) was compared to a regression of age, gen-
der, and complications. RESULTS: Over 124,000 mem-
bers were included in the study, about half male and fe-
male. About 85% were 45 or older. Approximately
82,000 (66%) had 0 comorbidities, 32,500 (26%) had 1,
and 10,000 (8%) had 1; 92% of those 18 had 0 co-
morbidities; 83% of those 18–44 did; 70% of those 45–
64 did; 52% of those 65 did. Similarly, 0.4% of those
18 had 1 comorbidity; 2.5% of those 18–44s, 6.6%
of those 45–64s, and 13% of those 65. The mean an-
nual cost was $820; with 0 comorbidities: $575; with 1:
$1,000; with 1: $2,300. The R2 for the regression with-
out complications 0.0059 (0.6% of log charges explained
by age and gender). The R2 with complications was
0.0487 (5% explained by age, gender and complica-
tions). This increase was highly significant (P  0.001).
CONCLUSIONS: Costs increased 8 times more due to
complications than age on a log scale. Substantial savings
may be realized by MCOs who manage their member’s
diabetes well.
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Diabetic foot ulcers are a common problem and result in
more than 50,000 lower extremity amputations each
year in the United States. Studies have suggested that be-
tween 25% and 50% of costs related to inpatient diabe-
tes care may be directly attributable to the diabetic foot.
OBJECTIVE: To compare the cost-effectiveness of treat-
ment with standard Wound Care Center (WCC) care
with treatment with Platelet Releasate (PR), an autolo-
gous product that provides concentrated platelet-derived
growth factor directly to the wound. METHODS: Our
analysis is based on effectiveness data from a database
created by Curative Health Services that includes data on
over 26,500 patients with diabetic neuropathic foot ul-
cers. Effectiveness was assessed as percentage of ulcers
healed at 32 weeks. Cost estimates were derived from the
Medicare Resource-Based Relative Value Scale. A sensi-
tivity analysis was conducted by adjusting several of the
variables associated with the cost-effectiveness equation.
RESULTS: Baseline cost for 32 weeks of therapy was
$2880.01 for WCC care (n  14,735) and $5680.01 for
PR (n  4701). Baseline effectiveness (with 95% confi-
dence intervals) for WCC and PR care were 38.0 (37.2,
38.8) and 48.4 (46.9, 49.8) respectively. The cost-effec-
tiveness ratio for PR vs WCC care was 269.23. This ratio
represents the marginal cost (in 1999 US dollars) of in-
creasing the chance of healing at 32 weeks by 1% by us-
ing PR rather than WCC care. CONCLUSIONS: While
PR is more expensive than WCC care, it does provide a
27% improvement in baseline healing at 32 weeks, and
the incremental increased cost must be weighed against
the substantial economic and psychological impact of
lower extremity amputation.
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Cost savings associated with detection and treatment of
diabetic eye disease has been well documented. However,
the cost-effectiveness of retinopathy screening in pediat-
ric patients with type I diabetes mellitus remains unclear.
In 1998, the Academy of Pediatrics released a new policy
regarding the ophthalmologic examination schedule for
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asymptomatic pediatric IDDM patients. Compared to
other guidelines, this one required prompt initiation,
more frequent eye exams, and earlier ophthalmologist re-
ferrals. OBJECTIVES: The purpose of this study was to
examine the cost-effectiveness of retinopathy screening in
pediatric patients with Type I diabetes under the new
policy. METHODS: Cost-effectiveness model was devel-
oped using Microsoft Excel 7.0, incorporating data from
previous epidemiological studies and clinical trials. Markov
Model was used, combined with sensitivity analysis. RE-
SULTS: Screening in pediatric patients was not only cost-
effective, but was actually cost saving from the societal
perspective. During the first 10 years of IDDM, retinopa-
thy screening was very cost-effective (CER  74$/QALY
at year 5). Starting from the 10th year, the intervention re-
sulted in an increasing level of cost and QALY savings.
The amount of QALY saved and cost savings both peaked
at 15 to 20 years after IDDM onset. Under 100% com-
pliance rate, screening produce average savings of $48,412
and Quality Adjusted Life Year (QALY) saved of 7.15
per patient. Our model was sensitive to the compliance
rate of screening; at 50% compliance rate, the total costs
for detection and treatment increased near 2-fold. Screen-
ing by ophthalmologists instead of primary care physi-
cians reduced the total costs by 53.5%. CONCLUSIONS:
Our analysis indicated that, under the new policy, the pro-
posed program reduced QALY loss, and reduced diabetic
retinopathy disease costs.
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OBJECTIVES: To evaluate the potential of clinical, de-
mographic and utilization factors in predicting treatment
costs for diabetic foot ulcers. METHODS: Retrospective
analysis of administrative outpatient pharmacy and med-
ical claims from 1/96–12/98 was conducted using Proto-
care Science’s Managed Care Database. Diabetic patients
were identified using diagnoses and medication claims.
Diagnosis of chronic skin ulcer of lower limbs defined
foot ulcer. Descriptive analysis of demographic, clinical,
and prior medical resource use information was per-
formed, followed by multivariate regression to estimate
the potential of these variables in explaining foot ulcer
treatment charges. RESULTS: The prevalence of diag-
nosed foot ulcers was 1.4% (2881 of the 212,563 identi-
fied diabetics). Patients with foot ulcers were older (mean
age 64.9 years vs. 60.7 years) and more likely to be male
(59.6% vs. 50%) than the non-foot ulcer diabetic popu-
lation. Diabetes-related complications and comorbidities
were common including skin infections, peripheral vascu-
lar disorders, and neurologic problems. During three
months following onset of foot ulcer, related care repre-
sented 40% of the $2596 average monthly charges per
patient. Using regression, demographic, clinical and prior
resource utilization information explained one-fifth of
the ulcer-related charges (R-square  0.22). Ulcer sever-
ity at onset, previous cellulitis or skin abscess, and pen-
toxifylline use were the strongest contributors. CON-
CLUSIONS: Although claims data cannot fully explain
variations in foot ulcer treatment costs, clinical factors,
such as markers for ulcer severity and active treatment of
peripheral vascular disease are predictors of treatment
costs. The correlation between previous skin problems
and treatment costs was negative, suggesting that height-
ened awareness through past experience may result in
lower treatment costs.
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OBJECTIVE: To compare direct medical costs of the
treatment of type-2 diabetic patients with hypertension,
hyperlipidemia, and no comorbidity. METHODS: The
study used an integrated medical and pharmacy claims
database from the Hawaii Medical Service Association.
Patients with at least one paid medical claim in the calen-
dar year 1995 for type-2 diabetes mellitus were selected.
Subsequently, these patients were segregated into three
mutually exclusive categories: patients with hypertension
as the sole comorbidity (Nhtn), patients with hyperlipi-
demia only (Nhlpd), and patients with no recorded comor-
bidity (Nnoco) in 1995. Average and median total medical
treatment costs as well as medical costs for the treatment
of diabetes and commonly associated comorbidities were
estimated for each population. RESULTS: Table 1 shows
sample size, age and gender distributions of three popula-
tions. Table 2 shows the total medical and diabetes and
associated comorbidity related medical costs of treat-
ment.
Table 1. Demography
Populations Sample size
Age
% femaleAverage Median
Nhtn 808 52 53 51.1
Nhlpd 657 50 51 47.6
Nnoco 623 45 47 52.3
